Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 1 (January)

1. 3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer.
   Biochem Biophys Res Commun, 340(2): 718-25. [Abstract] [Full-text]
2. Internal fiducial markers can assist dose escalation in treatment of prostate cancer: result of organ motion simulations.
   Phys Med Biol, 51(2): 269-85. [Abstract] [Full-text]
3. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation.
   Prostate, 66(3): 326-33. [Abstract] [Full-text]
4. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
   Prostate, 66(3): 305-16. [Abstract] [Full-text]
5. Thrombin receptor expression is upregulated in prostate cancer.
   Prostate, 66(3): 273-82. [Abstract] [Full-text]
6. Targeting of pericytes diminishes neovascularization and lymphangiogenesis in prostate cancer.
   Prostate, 66(3): 294-304. [Abstract] [Full-text]
7. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness.
   Prostate, 66(3): 317-25. [Abstract] [Full-text]
8. 90K/Mac-2 binding protein is expressed in prostate cancer and induces promatrilysin expression.
   Prostate, 66(3): 283-93. [Abstract] [Full-text]
9. Bystin in perineural invasion of prostate cancer.
   Prostate, 66(3): 266-72. [Abstract] [Full-text]
10. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
    Prostate, 66(3): 257-65. [Abstract] [Full-text]
11. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
    Prostate, 66(3): 248-56. [Abstract] [Full-text]
12. Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma.
    Prostate, 66(3): 227-34. [Abstract] [Full-text]
13. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
    Prostate, 66(3): 235-47. [Abstract] [Full-text]
14. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
    J Clin Oncol, 24(2): 268-73. [Abstract] [Full-text]
15. The effectiveness of screening for prostate cancer: a nested case-control study.
    Arch Intern Med, 166(1): 38-43. [Abstract] [Full-text]
16. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.
    Br J Cancer, 94(1): 128-35. [Abstract] [Full-text]
17. A preclinical study of prostate sentinel lymph node mapping with [99mTC]diethylenetetramine pentaacetic acid-mannosyl-dextran.
    J Urol, 175(2): 744-8. [Abstract] [Full-text]
18. Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer.
    J Urol, 175(2): 552-6. [Abstract] [Full-text]
19. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival.
    J Urol, 175(2): 547-51. [Abstract] [Full-text]
20. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    J Urol, 175(2): 533-6. [Abstract] [Full-text]
21. Biological correlates of p27 compartmental expression in prostate cancer.
    J Urol, 175(2): 528-32. [Abstract] [Full-text]
22. Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men.
    J Urol, 175(2): 523-7. [Abstract] [Full-text]
23. Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer.
    J Urol, 175(2): 518-21; discussion 521-2. [Abstract] [Full-text]
24. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
    J Urol, 175(2): 510-6; discussion 516-7. [Abstract] [Full-text]
25. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection.
    J Urol, 175(2): 500-4; discussion 504. [Abstract] [Full-text]
26. Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.
    J Urol, 175(2): 489-94. [Abstract] [Full-text]
27. Saturation technique does not improve cancer detection as an initial prostate biopsy strategy.
    J Urol, 175(2): 485-8. [Abstract] [Full-text]
28. North American white mitochondrial haplogroups in prostate and renal cancer.
    J Urol, 175(2): 468-72; discussion 472-3. [Abstract] [Full-text]
29. Targeting death receptors in bladder, prostate and renal cancer.
    J Urol, 175(2): 432-8. [Abstract] [Full-text]
30. Adiponectin as a growth inhibitor in prostate cancer cells.
    Biochem Biophys Res Commun, 340(4): 1158-66. [Abstract] [Full-text]
31. Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort.
    J Natl Cancer Inst, 98(2): 123-34. [Abstract] [Full-text]
32. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.
    Cancer Res, 66(2): 1234-40. [Abstract] [Full-text]
33. Increased expression of osteopontin contributes to the progression of prostate cancer.
    Cancer Res, 66(2): 883-8. [Abstract] [Full-text]
34. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms.
    Cancer Res, 66(2): 794-802. [Abstract] [Full-text]
35. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.
    Cancer Res, 66(2): 743-7. [Abstract] [Full-text]
36. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice.
    Cancer Res, 66(2): 613-21. [Abstract] [Full-text]
37. Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction.
    Mol Cell Biol, 26(3): 929-39. [Abstract] [Full-text]
38. NPC-14686 (Fmoc-l-homophenylalanine)-induced CaCa2+ increases and death in human prostate cancer cells.
    Life Sci, 78(9): 964-9. [Abstract] [Full-text]
39. Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors.
    BJU Int, 97(2): 404-9. [Abstract] [Full-text]
40. Twelve-month self-reported quality of life after retropubic radical prostatectomy: a prospective study with Rand 36-Item Health Survey (Short Form-36).
    BJU Int, 97(2): 274-8. [Abstract] [Full-text]
41. Prostate tissue and leukocyte levels of n-3 polyunsaturated fatty acids in men with benign prostate hyperplasia or prostate cancer.
    BJU Int, 97(2): 270-3. [Abstract] [Full-text]
42. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
    BJU Int, 97(2): 266-9. [Abstract] [Full-text]
43. Site of local anaesthesia in transrectal ultrasonography-guided 12-core prostate biopsy: does it make a difference?
    BJU Int, 97(2): 263-5. [Abstract] [Full-text]
44. Location of a positive biopsy as a predictor of surgical margin status and extraprostatic disease in radical prostatectomy.
    BJU Int, 97(2): 259-62. [Abstract] [Full-text]
45. Factors predisposing to the development of anastomotic strictures in a single-surgeon series of radical retropubic prostatectomies.
    BJU Int, 97(2): 255-8. [Abstract] [Full-text]
46. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    BJU Int, 97(2): 247-54. [Abstract] [Full-text]
47. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms.
    Radiology, 238(2): 597-603. [Abstract] [Full-text]
48. Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells.
    Oncogene, 25(4): 546-54. [Abstract] [Full-text]
49. Tumor-suppression function of transcription factor USF2 in prostate carcinogenesis.
    Oncogene, 25(4): 579-87. [Abstract] [Full-text]
50. Impact of race and baseline PSA on longitudinal PSA.
    Int J Cancer, 118(7): 1773-6. [Abstract] [Full-text]
51. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Expert Rev Anticancer Ther, 6(2): 259-68. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.